Company intelligence / Profile preview

CardiaTec

Cambridge, England, United Kingdompmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Other

Overview

CardiaTec has built the largest proprietary human cardiac tissue multiomics database by partnering with over 65 hospitals across the UK and US. The company uses advanced computational modeling and artificial intelligence to identify novel targets for cardiovascular therapeutics. As of mid-2025, it is progressing from platform development into wet lab validation of its first proprietary targets. No clinical results are available yet as programs are preclinical.

Therapeutic areas: Cardiovascular
Modalities: Modality agnosticSmall moleculeBiologic
Industry: Biotech

Partnerships

University of Cambridge/Han LabCollaborations with >65 hospitals for tissue/data collection

Beyond the preview

Go deeper on CardiaTec.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CardiaTec.

Explore the full profile